سعر بيرجيتا 420 مجم/14 مل 2026

Pertuzumab 420 mg/14 ml concentrate for intravenous infusion, single vial (HER2-directed monoclonal antibody).

• HER2-positive metastatic breast cancer (with trastuzumab and docetaxel) without prior anti-HER2 therapy or chemotherapy for metastatic diseasePopulation: AdultsDailyMed (US National Library of Medicine)
• HER2-positive early breast cancer: neoadjuvant (locally advanced, inflammatory or early stage >2 cm or node positive) and adjuvant treatment at high risk of recurrence, with trastuzumab and chemotherapyPopulation: AdultsDailyMed (US National Library of Medicine)

• Most common (>30%) with trastuzumab and docetaxel in MBC: diarrhea, alopecia, neutropenia, nausea, fatigue, rash, peripheral neuropathy.International label, same product · DailyMed (US National Library of Medicine)

• Known hypersensitivity to pertuzumab or any excipient.International label, same product · DailyMed (US National Library of Medicine)

• Boxed warning: left ventricular dysfunction (assess LVEF before and during treatment) and embryo-fetal toxicity (verify pregnancy status, effective contraception for 7 months after last dose).International label, same product · DailyMed (US National Library of Medicine)
• Infusion-related reactions and hypersensitivity/anaphylaxis, including fatal events; monitor and interrupt infusion as needed.International label, same product · DailyMed (US National Library of Medicine)

• Can cause fetal harm; oligohydramnios, delayed fetal kidney development and embryo-fetal death in monkeys; oligohydramnios sequence reported with trastuzumab.International label, same product · DailyMed (US National Library of Medicine)
• No data on pertuzumab in human milk; weigh benefits of breastfeeding against risks, considering the 7-month washout.International label, same product · DailyMed (US National Library of Medicine)

• Pertuzumab: Binds the HER2 extracellular dimerization domain, blocking ligand-dependent HER2 heterodimerization and downstream signalling.